Background: Epstein-Barr virus (EBV) infection has been associated with higher clinical activity and risk of multiple sclerosis (MS). Objective: To evaluate associations between EBV-specific humoral response and magnetization transfer ratio (MTR)-derived measure in MS patients and healthy controls (HCs). Methods: The study included 101 MS patients (69 relapsing-remitting multiple sclerosis (RRMS) and 32 secondary-progressive multiple sclerosis (SPMS)) and 41 HCs who underwent clinical, serological, and magnetic resonance imaging (MRI) investigations. MTR values of T1 or T2 lesion volume (LV), normalappearing (NA) brain tissue (NABT), gray matter (NAGM), and white matter (NAWM) were obtained. Enzyme-linked immunosorbent assay was used to quantify EBV antibody levels. Partial correlations corrected for MRI strength were used, and Benjamini-Hochberg-adjusted p-values < 0.05 were considered significant. Results: MS patients had significantly higher anti-EBV nuclear antigen-1 (EBNA-1) titer when compared to HCs (107.9 U/mL vs 27.8 U/mL, p < 0.001). Within the MS group, higher serum anti-EBNA-1 titer was significantly correlated with lower T1-LV MTR (r = -0.287, p = 0.035). Within the RRMS group, higher serum anti-EBNA-1 titer was associated with T1-LV MTR (r = -0.524, p = 0.001) and NAGM MTR (r = -0.308, p = 0.043). These associations were not present in HCs or SPMS patients. Conclusion: Greater EBV humoral response is associated with lower GM MTR changes and focal destructive lesion pathology in RRMS patients.
Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by early episodic demyelinating attacks and continuous neurodegenerative changes of the white and gray matter (WM and GM). 1 Although an interplay of multiple cardiovascular, environmental, and genetic risk factors have been suspected, the exact and specific MS pathophysiology still remains to be elucidated. Among the many proposed environmental contributors to MS pathogenesis, late primary Epstein-Barr virus (EBV) infection has remained as an important and continuously documented risk factor. 2 The exposure and extent of the EBV infection can be measured with a panel of anti-EBV biomarkers, including antibodies toward the anti-EBV early antigen (EA), anti-EBV viral capsid antigen (VCA), and anti-EBV nuclear antigen (EBNA). 2 In comparison to the anti-VCA antibodies which appear and peak during the early phase of the infectious course, the anti-EBNA-1 antibodies emerge slowly after 2-4 months of the symptom onset and may be correlated to the load of latent EBV-infected B-cells. 2 Accumulating evidence on the increasingly important role of B-cells in MS pathophysiology has been recently reported. 3 Moreover, the role of B-cells has been additionally corroborated by the recent success of B-cell-depleting therapies in decreasing MS-related disease activity. 4 The memory CD27 + B-cells have been especially related to the extent of the MS pathology, and they present with specific receptors that are used by the EBV to bind, infect, and consequently immortalize the cells. 5 Therefore, they provide suitable environment for the survival of undetectable and relatively stable levels of latent virus, in which infected B-cells act as the EBV reservoir. Furthermore, recent molecular studies demonstrated that EBVinduced B-cells increase in myelin immunogenicity and autophagy. 6 EBV infection allows upregulation of antigen-presenting capability of the B-cells by activating and streamlining the internal processes into more effective myelin presentation. 6 Therefore, the pool of EBV-infected B-cells would provide higher T-cell activation, ultimately leading to a larger attack toward brain myelin.
The effect of EBV infection on magnetic resonance imaging (MRI)-detected MS pathology has been only investigated with conventional measures like contrastenhancing lesions, T2 or T1 lesion volume (LV), and global brain volumes. 2 Studies examining both clinically definite MS and clinically isolated syndrome (CIS) patients have demonstrated associations between higher humoral response toward EBV with both greater T1 and T2 lesion number, lower cross-sectional brain volumes, and increased longitudinal atrophy rates. 7, 8 Furthermore, relapsing-remitting multiple sclerosis (RRMS) patients with the highest titer of anti-EBV antibodies showed more advanced neurodegenerative pathology, as indicated by increased T1 lesion number and greater cortical atrophy. 7 However, conventional MRI measures may not fully capture the full extent EBV's effect on myelin damage.
Magnetization transfer imaging (MTI) is a nonconventional MRI technique that has been increasingly utilized in MS studies. 9 The MTI-derived magnetization transfer ratio (MTR) relates to myelin status, axonal loss, and cell infiltration changes. 10 For an example, lower MTR values have been previously corroborated with histopathological loss of WM and GM myelin content. 10, 11 Therefore, the MTI technique is a convenient, noninvasive method to investigate associations between hypothesized contributors to potential MS-related demyelination or remyelination processes. 12 Based on this background, we hypothesized that MS patients with higher humoral anti-EBV response will present with lower brain myelin levels as measured by in vivo MTI.
Materials and methods

Study population
The study population utilized in this analysis was part of a larger, prospective study of cardiovascular, environmental, and genetic risk factors in MS (CEG-MS) that enrolled over 1000 subjects with CIS, MS, healthy controls (HCs), and other neurologic diseases (OND). This sub-study inclusion criteria were as follows: (1) age of 18-75 years old, (2) being an MS patient as diagnosed by the 2010-revised McDonald criteria, 13 (3) being an HC without prior or current neurological disorder, (4) obtaining MRI with standardized protocol that included specific MTI sequence on 1.5 T or 3 T scanners, (5) clinical examination within 30 days from the MRI visit, and (6) serum samples obtained at the day of the MRI examination for EBV status determination. On the other hand, the exclusion criteria included the following: (1) clinical relapse or steroid use within 30 days of the MRI visit and (2) pregnant or nursing mothers. An experienced neurologist performed full clinical and neurological examination and the Kurtzke's Expanded Disability Status Scale (EDSS) scores were determined. 14 With the use of standardized study questionnaires, additional information regarding the history of mononucleosis was collected.
The study participants signed written informed consent, and the study was approved by the University at Buffalo Institutional Review Board (IRB).
MRI acquisition and analysis
The MS patients were scanned using either 3 T or 1.5 T General Electric Signa Excite HD 12.0 Twin Speed eight-channel scanners (GE, Milwaukee, WI, USA) and eight-channel head and neck (HDNV) receive coil using standardized MRI protocols, whereas the HCs were scanned only on the 3 T scanner with the same protocols. Of the 101 MS patients, 62 were scanned on 3 T scanner and 39 were scanned on the 1.5 T. The 3 T sequences used included the following: A semi-automated contouring/thresholding technique was used to measure the T1 and T2 LV masks, as described elsewhere. 15 In addition, the global tissue segmentations of GM and WM were obtained by SIENAX cross-sectional software (version 2.6, FMRIB, Oxford, UK). 16 T1 hypointensities were filled prior to segmentation to avoid tissue misclassification. 17 Normal-appearing brain tissue (NABT), normal-appearing white matter (NAWM), and normal-appearing (NAGM) were derived after removing voxels that corresponded to the T2 lesions.
As previously published, the MTR values were calculated by digital subtraction and use of the standardized formula
where M 0 is the pixel intensity of the sequence without the MT pulse, and M s is the same pixel with the MT pulse. Mean MTR values were calculated within lesions, NABT, NAWM, and NAGM. All analyses performed were blinded to the clinical characteristics.
EBV humoral response analysis
The status of anti-EBNA-1 IgG antibodies was determined by the Department of Pharmaceutical Sciences at University at Buffalo. Analysis was blinded to the clinical status and the severity of the MS disease. Enzyme-linked immunosorbent assay (ELISA) kit (Diamedix Corporation, Miami, FL, USA) was used to quantify the antibody levels, which were normalized based on the manufacturer's cut-off standards. Serial dilution of manufacturer-provided positive control samples allowed generation of standard curves. 7 The cut-off was calibrated by manufacturer-provided plasma, which is weakly reactive to anti-EBNA-1 antibodies. The quality control was additionally performed by paired sera controls (Index Value between 3.0 and 4.0), which underwent four-fold dilution. Both the low positive (low range of the assay) and negative control were included in each test run. The study subject sera was diluted in 1:21 ratio.
Statistical analysis
The statistical analysis were performed using SPSS 25.0 (IBM, Armonk, NY, USA). For demographic and clinical comparisons between the HCs and MS patients, χ 2 test, Student's t-test, and Mann Whitney U-test were used according to the normality of the data. The normal distribution of the data was determined using Kolmogorov-Smirnov test. The data distribution was further analyzed with Q-Q plot visualization. Due to the non-parametric nature of the anti-EBNA-1 titer and the MTR values, Spearman's non-parametric rank correlations were utilized. Furthermore, quartile analysis based on the anti-EBNA-1 titer was performed. Since 39 MS patients were acquired on 1.5 T scanner and 62 on 3 T scanner, partial non-parametric correlation corrected for the MRI field strength was utilized. Finally, the partial non-parametric correlations were repeated, correcting for disease duration.
In order to graphically illustrate the data, scatter plots were employed, where both the MTR values and anti-EBNA-1 titer were transformed using the natural logarithm. Both for the MS versus HCs and the RRMS versus secondary-progressive multiple sclerosis (SPMS) analyses, multiple comparison correction/ false discovery rate (FDR) was performed using the Benjamini-Hochberg procedure and adjusted p-values lower than 0.05 were considered statistically significant. Post hoc power analysis for the significant findings determined the minimal sample size based on study power at 60%, 70%, 80%, 90%, and 95% (Supplemental Table 1 ). Finally, the differential relationship of anti-EBNA-1 titer and the MTR values seen between different MS phenotypes was tested by general linear model (GLM) analysis. The associations between brain MTR values and the interaction between disease phenotype and anti-EBNA-1 levels was additionally reported.
Results
Study population
The demographic, clinical, and MTR characteristics of the study population are shown in Table 1 . The study population consisted of 41 HCs and 101 MS patients who showed no significant differences in age (mean 45.4 vs 46.9, t-test p = 0.681) and sex ( (2), intravenous immunoglobulins (1), and naltrexone (1) . The patient treated with intravenous immunoglobulins (IVIG) received the IVIG infusions after a relapse which occurred 10 months before study entry. MTR value comparison utilizing only 3 T-scanned MS patients and 3 T HCs yielded similar statistical differences (T2 p = 0.005, NAWM p = 0.001, NAGM p < 0.001, and NABT p < 0.001). Significant associations and p-values are shown in bold.
the contrary, there were no statistical difference in the MTR values between RRMS and SPMS patients ( Table 2 ). The comparison between the groups using only 3 T-derived MTR values yielded similar statistical differences. Although numerically higher in the RRMS group, there were no significant anti-EBNA-1 titer differences between the RRMS and SPMS subgroups (median 132.6 U/mL vs 80.4 U/mL, Mann-Whitney U-test p = 0.635).
MTR associations with serum anti-EBNA-1 titer levels in HCs and MS patients.
Within the MS patients, higher serum anti-EBNA-1 titer was significantly associated with lower T1 lesion MTR (r = -0.287, p = 0.035). The serum anti-EBNA-1 titer was not associated with the MTR measures value in HCs ( Table 3 ).
The MS population was also categorized based on anti-EBNA-1 titer quartiles (Supplemental Figure 1 ) and both T1 lesion MTR and NAGM MTR values were the lowest within the first quartile (one-way analysis of variance (ANOVA), p = 0.001 and p = 0.023, respectively). There were no age nor disease duration differences between the anti-EBNA-1 quartiles.
Likewise, the RRMS patients showed associations of higher serum anti-EBNA-1 titer and lower T1 lesion MTR (r = -0.524, p < 0.001) and NAGM (r = -0.308, p = 0.043; Table 4 ). In contrast, these associations were not present within the SPMS group. Additional analysis utilizing dichotomization based on the median NAGM MTR values was performed. RRMS patients within the lower NAGM MTR group had significantly higher anti-EBNA-1 titer when compared to the RRMS group with the higher NAGM MTR (median 195.8 vs 53.4, p < 0.001). The graphical representation of the findings is shown in Figure 1 . The effect of the disease phenotype on the association between the T1 lesion MTR values and anti-EBNA-1 titer was confirmed by the GLM analysis (interaction effect of F 1,97 = 9.05, p = 0.004). On the other hand, such interaction between the disease phenotype and anti-EBNA-1 titer was not significantly associated with the NAGM MTR values (F 1,97 = 2.25, p = 0.137). Table  2 ) confirmed the association between higher anti-EBNA-1 titer and lower T1 lesion MTR values (r = -0.353, p = 0.022 and r = -0.532, p = 0.007, for total MS population and RRMS only, respectively). The association between higher anti-EBNA-1 titer and T1 lesion MTR is additionally illustrated in Figure 2 , and a case example of an RRMS patient with potentially large pool of EBV-infected B-cells (measured as very high anti-EBNA-1 titer) and accompanying T1-hypointensities is demonstrated in Figure 3 . After correcting for the disease duration, the correlations between anti-EBNA-1 titer and T1 lesion MTR in the total MS population (r = -0.265, FDR-unadjusted p = 0.023), anti-EBNA-1 titer and T1 lesion in RRMS (r = -0.503, FDR-unadjusted p < 0.001), and anti-EBNA-1 titer and NAGM in RRMS (r = -0.3, FDRunadjusted p = 0.014) remained significant.
Separate analysis within the smaller MS population scanned only on the 3 T scanner (Supplemental
Discussion
This is one of the first studies to demonstrate an association between greater anti-EBV humoral response and in vivo, MRI-derived, lower global and MS lesion MTR levels. Conversely, these associations were not observed in the age-matched HC population. The associations of higher anti-EBNA-1 levels and potentially lower myelin levels were primarily driven by the active RRMS cohort and located at sites of T1 lesions, and in the NAGM.
Late EBV infection has been implicated as a contributor to increased risk of developing MS and further increased disease activity. 18 Several studies have shown an association of higher serum anti-EBNA-1 IgG antibodies and a "dose-dependent" increase of the MS risk. 19 Individuals with IgG titers higher than 320 U/mL had 36-fold higher MS risk than individuals with <20 U/mL, and eight-fold higher than individuals with <320 U/mL. 19 In line with previous reports, the MS patients from our cohort had four-fold higher anti-EBNA-1 levels than the HCs. Furthermore, MS patients had double the frequency of infectious mononucleosis, a difference that was not significant, probably because of the relatively low sample size of the study. Several epidemiological studies have demonstrated associations between history of infectious mononucleosis and consequently increased risk of MS. 20, 21 Since the development of MS cannot be attributed to any single factor, the interplay of environmental effects should be assessed as a joint effect of their interactions. 22 A recent study calculated the attributable fraction for each known MS risk factor and concluded that previous history of infectious mononucleosis constitutes 30.8% of the total environmental effect. 22 Previous studies have only examined the association between active EBV infection and conventional MS-related MRI-detected pathology. 23, 24 For an example, MS patients with cerebrospinal fluid presence of EBV DNA do present with more gadoliniumenhancing lesions. 25 Similarly, a larger cross-sectional study showed that patients within the highest quartile of anti-VCA levels had significantly higher T2-LV, higher number and volume of T1-hypointensities and lower brain volume. 7 In line with our association of higher anti-EBV response and lower NAGM myelin levels, the previous study also showed an association of greater cortical pathology and higher anti-EBV levels, a finding which was only seen within the relapsing MS group. 7 To the best of our knowledge, this is the first report regarding the effect of EBV and in vivo MTR-derived myelin content and thus provides further evidence regarding the supposed role of EBV in MS pathology.
Multiple latent and lytic EBV proteins, like the latent membrane protein 1 (LMP-1) and the immediateearly lytic gene product (BZLF1) have been detected in MS brains with prevalent presence of CD138 + plasma cells. Furthermore, our finding of an association between high anti-EBNA-1 titer and lower T1 lesion MTR was further corroborated by reports of immunohistochemical demonstration of the lytic EBV phenotype within chronic MS lesions. 26 Similarly, a recent histopathological study utilized laser-cut SPMS lesioned brain samples and demonstrated upregulation and expression of diversity of genes associated with latent EBV infection such as EBNA3A, LMP1, and LMP2A. 27 Conforming to our example demonstrated in Figure 3 , recent fulminant and lethal relapse of a natalizumab-discontinuing RRMS patient has been attributed to extensive demyelination and infiltration of EBV-infected B-cells. 28 Since most histopathological studies are performed on autopsied brains from patients with long-standing SPMS, they may not reflect the full scope of EBV's effect earlier in the disease. The significant associations found in this study were restricted to the RRMS group, findings in line with the early clinical effect of EBV on the increased MS risk and on increased relapse rate. Our general linear model additionally corroborated the differential phenotype effect, demonstrating specific RRMS contribution. Moreover, the findings between the higher anti-EBNA-1 titer and decreased MTR signal remained significant even after correction for patients' disease duration. Therefore, the specific findings of lower MTR signal may be temporally restricted within the period of inflammatory activity which results with both pathological changes like acute demyelination and edema and concurrent B-cell influx and viral particle shedding.
On the other hand, lower NAGM MTR may potentially be explained by either the presence of B-cell infiltrated intracortical lesions or by local cortical demyelination associated with meningeal, EBV-infected, B-cell-rich, tertiary lymphoid follicles. A post-mortem examination of SPMS patients has demonstrated the presence of early EBV lytic proteins (BZLF1 and BFRF1) in all of the examined intracortical perivascular spaces. 29 Furthermore, the study also showed that cortical lesions themselves were infiltrated with EBV-infected B-cells, which may provide local maintenance of the B-celldriven inflammatory process. 29 A subset of MS patients presents with intrameningeal follicles, which contain proliferating B-cells, strongly suggesting the formation of an immune germinal center. 30 Therefore, the follicle-like structures might represent a site of constantly maintained intracerebral pool of EBV-harboring B-cells. 31 In line with the proposed meningeal origin of cortical demyelination, quantitative assessment of cases with the presence of the aforementioned follicles had six-fold greater lesioned GM area and threefold greater total cortical demyelination. 32 On the other hand, patients with tertiary follicle-like structure had no statistical difference in the amount of lesioned WM area. 32 The ectopic B-cell-rich, follicle-like structures additionally contribute to a gradient of demyelination, greatest at the pial surface. This finding would implicate the diffusion of soluble factors that originate from the B-cells located in the meninges. 33 In addition to demyelination, there is also a gradient affecting both GM lesions, death of oligodendrocytes, increased microglial activation, and overall decrease in neuron density. 33 Furthermore, leptomeningeal perivascular inflammation can be demonstrated in vivo by long-delay, post-contrast 3D FLAIR imaging and visualization of leptomeningeal contrast enhancement. 34 A postmortem autopsy study also confirmed subpial confluent cortical demyelination around the sulci, which harbor the aforementioned abnormal contrast retention. 35 Although the presence of the meningeal tertiary follicle-like structures are usually associated with long-standing progressive MS disease, a recent report has demonstrated their presence in early and acute MS patients. 36 The overall cortical pathology seen in these early MS patients (2 years of disease duration) was highly associated with the presence of meningeal inflammation. 36 More importantly, almost 20% of the GM lesions seen within the early MS patients with leptomeningeal inflammation were classified as actively demyelinating (CD68 + macrophages which contain myelin inclusions). Conversely, despite the presence of meningeal follicles, none of the SPMS patients presented with actively demyelinating lesions. 36 The discrepancies in the RRMS versus SPMS associations may be further explained by the location of the EBV-infected B-cells and the availability to shed viral particles into the circulation. Although SPMS patients have higher percentage of leptomeningeal tertiary follicles, those EBV-infected B-cells may be fully compartmentalized behind an already repaired blood-brain barrier (BBB). On the other hand, EBVinfected B-cells that are actively participating within an acute lesioned process have the concurrent availability of disrupted BBB which would allow shedding of viral particles into the circulation. This working hypothesis can be supplemented by a recent attempt to deplete the meningeal B-cells by intrathecal administration of anti-CD20 agents. Initial mice model studies showed that administration of anti-CD20 medications are able to deplete the meningeal B-cells. 37 Based on these preclinical findings, early phase I clinical trials were initiated. 38 Progressive MS patients with MRI-documented leptomeningeal contrast enhancement (suggestive of meningeal B-cell accumulation) were treated with intrathecal anti-CD20 medication. 38 Although the treatment resulted with successfully depleted peripheral B-cells population, the medication did not change the initial extent of meningeal inflammation. 38 Therefore, the compartmentalized nature of the SPMS EBV-infected B-cells may prevent free diffusion of viral particles and ultimately diffusion of the targeted therapy.
One potential limitation of this study is the use of additional MS patients that were scanned on 1.5 T MRI scanner. However, this further increased our sample size and the independent analyses demonstrated a similar effect in both groups regardless of the scanner used. Another potential limitation is the interpretation of the MTR changes. Although lower MTR levels have been histologically associated with lower myelin content, this measure may be additionally influenced by axonal damage and swelling. A recent investigation suggested that the T1-weighted hypointensities and the MTR signal can be considerably affected by axonal swelling, activation of the microglia, astrocytosis, and serum proteins despite the absence of demyelination. 39 Analysis of the tertiary meningeal follicles, their harboring EBV load, and local GM demyelination may explain our findings. Future MTR and EBV studies in MS patients with and without presence of leptomeningeal contrast enhancement are needed. Future improvement in susceptibility-based imaging and classification of chronically-active (slowlyexpanding) versus inactive lesions may further help in pinpointing the factors that influence the anti-EBNA-1 and T1 lesion MTR association. 40 Given the controversial nature of the overall EBV effect on MS pathology, activity, and progression, the findings should be carefully considered and further replicated. Potential analysis regarding the effect of B-cell depleting therapy on the EBV titer is also highly warranted. Finally, while our study was powered at 80% to show the association between anti-EBNA-1 and MTR of T1-LV and NAGM (Supplemental Table 1 ) in total and RRMS population, the SPMS cohort was underpowered to investigate these associations. The finding of different EBNA-T1 MTR relationships between the RRMS and SPMS phenotypes should be further examined. Therefore, future studies including larger sample size of SPMS patients should explore these associations.
In conclusion, we demonstrated an association between greater humoral response toward EBV and more severe pathology within chronic T1-hypointense lesions and in the cerebral GM. Further confirmation of these results is warranted.
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